Download PDF
Thromb Haemost 2018; 118(08): 1470-1480
DOI: 10.1055/s-0038-1666870
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R−/−) Mice

Renata Feuerborn   *
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Manuela Besser   *
2   Department of Anaesthesiology and Intensive Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Francesco Potì
3   Department of Medicine and Surgery–Unit of Neurosciences, University of Parma, Parma, Italy
4   Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
Ralph Burkhardt
5   Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, University of Leipzig, Leipzig, Germany
,
Gabriele Weißen-Plenz
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Uta Ceglarek
5   Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, University of Leipzig, Leipzig, Germany
,
Manuela Simoni
4   Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
Richard L. Proia
6   Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States
,
Hendrik Freise
2   Department of Anaesthesiology and Intensive Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Jerzy-Roch Nofer
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
› Author Affiliations Funding Grant NO406/3–1 from Deutsche Forschungsgemeinschaft (DFG) to J.-R.N., grant NO110816 from the Innovative Medizinische Forschung (IMF) to J.-R.N., intramural resources of the Center for Laboratory Medicine to J.-R.N., FIRB-IDEAS grant RBID08777T from the Italian Ministry of Education, University and Research to J.-R.N. and M.S. and the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease to R.P.
Further Information

Publication History

16 January 2018

24 May 2018

Publication Date:
30 July 2018 (online)

    Permissions and Reprints

Abstract

Background Sphingosine-1-phosphate (S1P) is a bioactive lysosphingolipid and a constituent of high-density lipoprotein (HDL) exerting several atheroprotective effects in vitro. However, the few studies addressing anti-atherogenic effects of S1P in vivo have led to disparate results. We here examined atherosclerosis development in low-density lipoprotein receptor (LDL-R)-deficient (LDL-R−/−) mice with elevated endogenous S1P levels.

Methods and Results Sub-lethally irradiated LDL-R−/− mice were transplanted with bone marrow deficient in sphingosine kinase 2 (SphK2), which led to the elevation of S1P concentrations in erythrocytes, plasma and HDL by approximately 1.5- to 2.0-fold in SphK2−/−/LDL-R−/− mice. Afterwards, mice were fed a Western diet for 14 weeks. Elevation of endogenous S1P significantly reduced atherosclerotic lesion formation by approximately half without affecting the plasma lipid profile. Furthermore, the macrophage content of atherosclerotic lesions and lipopolysaccharide-induced monocyte recruitment to the peritoneal cavity were reduced in SphK2−/−/LDL-R−/− mice. Studies using intra-vital microscopy revealed that endogenous S1P lowered leukocyte adhesion to capillary wall and decreased endothelial permeability to fluorescently labelled LDL. Moreover, SphK2−/−/LDL-R−/− mice displayed decreased levels of vascular cell adhesion molecule 1 in atherosclerotic lesions and in plasma. Studies in vitro demonstrated reduced monocyte adhesion and transport across an endothelial layer exposed to increasing S1P concentrations, murine plasma enriched in S1P or plasma obtained from SphK2-deficient animals. In addition, decreased permeability to fluorescence-labelled dextran beads or LDL was observed in S1P-treated endothelial cells.

Conclusion We conclude that raising endogenous S1P levels exerts anti-atherogenic effects in LDL-R−/− mice that are mediated by favourable modulation of endothelial function.

Keywords

sphingosine-1-phosphate - high-density lipoproteins - sphingosine kinase 2 - endothelial cells - atherosclerosis

* Renata Feuerborn and Manuela Besser contributed equally to this study.


Supplementary Material

 

  • References

  • 1 Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 2015; 125 (04) 1379-1387
    CrossrefPubMedGoogle Scholar
  • 2 Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res 2016; 62: 93-106
    CrossrefPubMedGoogle Scholar
  • 3 Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011; 111 (10) 6299-6320
    CrossrefPubMedGoogle Scholar
  • 4 Xiong Y, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol 2014; 378: 85-105
    PubMedGoogle Scholar
  • 5 Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta 2014; 1841 (10) 1403-1412
    CrossrefPubMedGoogle Scholar
  • 6 Bolick DT, Srinivasan S, Kim KW. , et al. Sphingosine-1-phosphate prevents tumor necrosis factor-α-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 2005; 25 (05) 976-981
    CrossrefPubMedGoogle Scholar
  • 7 Kimura T, Tomura H, Mogi C. , et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281 (49) 37457-37467
    CrossrefPubMedGoogle Scholar
  • 8 Schuchardt M, Tölle M, Prüfer J, van der Giet M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol 2011; 163 (06) 1140-1162
    CrossrefPubMedGoogle Scholar
  • 9 Tölle M, Pawlak A, Schuchardt M. , et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28 (08) 1542-1548
    CrossrefPubMedGoogle Scholar
  • 10 Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 2013; 1831 (01) 203-212
    CrossrefPubMedGoogle Scholar
  • 11 Abbasi T, Garcia JG. Sphingolipids in lung endothelial biology and regulation of vascular integrity. Handb Exp Pharmacol 2013; 216 (216) 201-226
    PubMedGoogle Scholar
  • 12 Christoffersen C, Nielsen LB. Apolipoprotein M: bridging HDL and endothelial function. Curr Opin Lipidol 2013; 24 (04) 295-300
    CrossrefPubMedGoogle Scholar
  • 13 Karuna R, Park R, Othman A. , et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011; 219 (02) 855-863
    CrossrefPubMedGoogle Scholar
  • 14 Argraves KM, Sethi AA, Gazzolo PJ. , et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10: 70
    CrossrefPubMedGoogle Scholar
  • 15 Sattler K, Gräler M, Keul P. , et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol 2015; 66 (13) 1470-1485
    CrossrefPubMedGoogle Scholar
  • 16 Potì F, Simoni M, Nofer JR. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc Res 2014; 103 (03) 395-404
    CrossrefPubMedGoogle Scholar
  • 17 Levkau B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol 2015; 6: 243
    PubMedGoogle Scholar
  • 18 Potì F, Gualtieri F, Sacchi S. , et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol 2013; 33 (07) 1505-1512
    CrossrefPubMedGoogle Scholar
  • 19 Nofer JR, Bot M, Brodde M. , et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115 (04) 501-508
    CrossrefPubMedGoogle Scholar
  • 20 Keul P, Tölle M, Lucke S. , et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27 (03) 607-613
    CrossrefPubMedGoogle Scholar
  • 21 Galvani S, Sanson M, Blaho VA. , et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal 2015; 8 (389) ra79
    CrossrefPubMedGoogle Scholar
  • 22 Gonzalez L, Qian AS, Tahir U, Yu P, Trigatti BL. Sphingosine-1-phosphate receptor 1, expressed in myeloid cells, slows diet-induced atherosclerosis and protects against macrophage apoptosis in LDLR KO mice. Int J Mol Sci 2017; 18 (12) E2721
    CrossrefPubMedGoogle Scholar
  • 23 Skoura A, Michaud J, Im DS. , et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31 (01) 81-85
    CrossrefPubMedGoogle Scholar
  • 24 Bosteen MH, Madsen Svarrer EM, Bisgaard LS. , et al. Effects of apolipoprotein M in uremic atherosclerosis. Atherosclerosis 2017; 265: 93-101
    CrossrefPubMedGoogle Scholar
  • 25 Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25 (24) 11113-11121
    CrossrefPubMedGoogle Scholar
  • 26 Ceglarek U, Dittrich J, Helmschrodt C. , et al. Preanalytical standardization of sphingosine-1-phosphate, sphinganine-1-phosphate and sphingosine analysis in human plasma by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2014; 435: 1-6
    CrossrefPubMedGoogle Scholar
  • 27 Poti F, Bot M, Costa S. , et al. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice. Thromb Haemost 2012; 107 (03) 552-561
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Eschert H, Sindermann JR, Scheld HH, Breithardt G, Weissen-Plenz G. Vascular remodeling in ApoE-deficient mice: diet dependent modulation after carotid ligation. Atherosclerosis 2009; 204 (01) 96-104
    CrossrefPubMedGoogle Scholar
  • 29 Nitschke Y, Weissen-Plenz G, Terkeltaub R, Rutsch F. Npp1 promotes atherosclerosis in ApoE knockout mice. J Cell Mol Med 2011; 15 (11) 2273-2283
    CrossrefPubMedGoogle Scholar
  • 30 Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol 2010; 184 (08) 4133-4142
    CrossrefPubMedGoogle Scholar
  • 31 Bot M, Van Veldhoven PP, de Jager SC. , et al. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. PLoS One 2013; 8 (05) e63360
    CrossrefPubMedGoogle Scholar
  • 32 Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013; 13 (10) 709-721
    CrossrefPubMedGoogle Scholar
  • 33 Hedrick CC. Lymphocytes in atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35 (02) 253-257
    CrossrefPubMedGoogle Scholar
  • 34 Xiong Y, Lee HJ, Mariko B. , et al. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem 2013; 288 (45) 32563-32573
    CrossrefPubMedGoogle Scholar
  • 35 Maiuri MC, Grassia G, Platt AM, Carnuccio R, Ialenti A, Maffia P. Macrophage autophagy in atherosclerosis. Mediators Inflamm 2013; 2013: 584715
    PubMedGoogle Scholar
  • 36 Kimura T, Tomura H, Mogi C. , et al. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 2006; 18 (06) 841-850
    CrossrefPubMedGoogle Scholar
  • 37 Kimura T, Mogi C, Tomura H. , et al. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol 2008; 181 (10) 7332-7340
    CrossrefPubMedGoogle Scholar
  • 38 Shimizu H, Takahashi M, Kaneko T. , et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005; 111 (02) 222-229
    CrossrefPubMedGoogle Scholar
  • 39 Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006; 345 (01) 85-92
    CrossrefPubMedGoogle Scholar
  • 40 Ogawa R, Takahashi M, Hirose S. , et al. A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun 2007; 361 (03) 621-628
    CrossrefPubMedGoogle Scholar
  • 41 Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ. AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 2009; 216 (1-2): 59-65
    CrossrefPubMedGoogle Scholar
  • 42 Bajwa A, Jo SK, Ye H. , et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21 (06) 955-965
    CrossrefPubMedGoogle Scholar
  • 43 Christensen PM, Bosteen MH, Hajny S, Nielsen LB, Christoffersen C. Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Sci Rep 2017; 7 (01) 14983
    CrossrefPubMedGoogle Scholar
  • 44 Christensen PM, Liu CH, Swendeman SL. , et al. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1. FASEB J 2016; 30 (06) 2351-2359
    CrossrefPubMedGoogle Scholar
  • 45 Ruiz M, Frej C, Holmér A, Guo LJ, Tran S, Dahlbäck B. High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler Thromb Vasc Biol 2017; 37 (01) 118-129
    CrossrefPubMedGoogle Scholar
  • 46 Ruiz M, Okada H, Dahlbäck B. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium. Lipids Health Dis 2017; 16 (01) 36
    CrossrefPubMedGoogle Scholar